{"id":"angiotensin-blockade","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperkalemia"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Cough (ACE inhibitors)"},{"rate":null,"effect":"Renal impairment"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Angiotensin II is a potent vasoconstrictor that plays a central role in blood pressure regulation and cardiovascular remodeling. By blocking angiotensin II receptors (ARBs) or inhibiting angiotensin-converting enzyme (ACE inhibitors), this mechanism reduces peripheral vascular resistance, decreases aldosterone secretion, and promotes sodium and water excretion, leading to reduced blood pressure and improved cardiac function.","oneSentence":"Angiotensin blockade inhibits the renin-angiotensin-aldosterone system (RAAS) to reduce vasoconstriction and lower blood pressure.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:40:38.709Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Heart failure"},{"name":"Post-myocardial infarction"},{"name":"Diabetic nephropathy"}]},"trialDetails":[{"nctId":"NCT07458880","phase":"NA","title":"Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure Control","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2026-03-01","conditions":"Intracerebral Hemorrhage","enrollment":140},{"nctId":"NCT07444203","phase":"","title":"Transformative Research in Diabetic Nephropathy 2.0","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-11-12","conditions":"Diabetic Nephropathies, Kidney Diseases, Renal Insufficiency, Chronic","enrollment":200},{"nctId":"NCT03593317","phase":"PHASE2","title":"Blockade of the Renin-angiotensin-aldosterone System in Patients With ARVD","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2024-12-20","conditions":"Arrhythmogenic Right Ventricular Dysplasia","enrollment":120},{"nctId":"NCT06933706","phase":"PHASE2","title":"Losartan to Improve Outcomes After Multi-ligament Knee Injury","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2025-10-01","conditions":"Multi-ligament Knee Injury","enrollment":90},{"nctId":"NCT05834803","phase":"NA","title":"Effects of Percutaneous Transluminal Renal Angioplasty of Atherosclerotic Renal Artery Stenosis in High-Risk Patients.","status":"RECRUITING","sponsor":"University of Aarhus","startDate":"2023-06-26","conditions":"Renovascular Hypertension, Renovascular Hypertension With Renal Failure, Heart Failure","enrollment":80},{"nctId":"NCT03188887","phase":"PHASE3","title":"Treatment of IgA Nephropathy According to Renal Lesions","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-02-20","conditions":"IgA Nephropathy","enrollment":62},{"nctId":"NCT02966665","phase":"PHASE1","title":": Vascular Function in Health and Disease","status":"RECRUITING","sponsor":"Russell Richardson","startDate":"2008-09","conditions":"Chronic Obstructive Pulmonary Disease, Pulmonary Artery Hypertension, Heart Failure","enrollment":420},{"nctId":"NCT06625346","phase":"","title":"Clinical Response of EXTOR (Amlodipine/Valsartan) in Newly Diagnosed Hypertensive Patients.","status":"RECRUITING","sponsor":"The Searle Company Limited Pakistan","startDate":"2024-09-28","conditions":"Hypertension","enrollment":420},{"nctId":"NCT03418779","phase":"PHASE2, PHASE3","title":"Treatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With Immunosuppression Therapies in IgA Nephropathy Patients With High-risk of ESRD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guang'anmen Hospital of China Academy of Chinese Medical Sciences","startDate":"2019-07-04","conditions":"IgA Nephropathy at High Risk of Developing ESRD","enrollment":60},{"nctId":"NCT06499948","phase":"PHASE4","title":"Albuminuria Lowering Effect of Dapagliflozin, Spironolactone and Their Combination in Adult Patients with Alport Syndrome (COMBINE-ALPORT)","status":"RECRUITING","sponsor":"Stefan Lujinschi","startDate":"2024-02-26","conditions":"Alport Syndrome, Thin Basement Membrane Disease, Alport Nephropathy","enrollment":34},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT05269615","phase":"PHASE4","title":"Exercise-induced Erythropoiesis: the Mechanistic of Angiotensin II","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2023-03-20","conditions":"Exercise Physiology","enrollment":80},{"nctId":"NCT02597361","phase":"PHASE3","title":"Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome (ARCADE)","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-01","conditions":"Ehlers-Danlos Syndrome, Vascular Type","enrollment":61},{"nctId":"NCT02245230","phase":"PHASE1","title":"Cardiovascular Effects of Angiotensin (1-7) in Essential Hypertension","status":"TERMINATED","sponsor":"Vanderbilt University","startDate":"2015-01","conditions":"Hypertension, Hypertension, Essential","enrollment":24},{"nctId":"NCT06187493","phase":"NA","title":"Treatment of Patients With Diabetic Kidney Disease","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2024-01-01","conditions":"Diabetic Kidney Disease","enrollment":70},{"nctId":"NCT03686696","phase":"PHASE4","title":"Randomized Evaluation of Beta Blocker and ACEI/ARB Treatment in MINOCA Patients - MINOCA-BAT","status":"TERMINATED","sponsor":"Uppsala University","startDate":"2018-12-16","conditions":"Myocardial Infarction With Non-obstructive Coronary Arteries","enrollment":198},{"nctId":"NCT06026787","phase":"PHASE4","title":"Clinical Value of Adding Dapagliflozin in Patients With Nephrotic Syndrome","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-08-01","conditions":"Nephrotic Syndrome, Sodium-Glucose Transporter 2 Inhibitors","enrollment":60},{"nctId":"NCT02046395","phase":"PHASE4","title":"Effect of Renin-angiotensin-system Blockade on Urinary Free Light Chains in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Tulane University School of Medicine","startDate":"2012-01","conditions":"Type 2 Diabetes, Hypertension","enrollment":28},{"nctId":"NCT04508985","phase":"NA","title":"The McGill RAAS-COVID-19 Trial","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2020-10-01","conditions":"COVID-19, Cardiovascular Diseases","enrollment":46},{"nctId":"NCT03502031","phase":"PHASE4","title":"Safety and Efficacy of Two Year of RAAS Alone or in Combination With Spironolactone Therapy","status":"UNKNOWN","sponsor":"James A. Tumlin, MD","startDate":"2018-10-01","conditions":"Renal Insufficiency, Chronic, Diabetic Nephropathy Type 2","enrollment":72},{"nctId":"NCT04394117","phase":"PHASE4","title":"Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease","status":"COMPLETED","sponsor":"The George Institute","startDate":"2020-06-19","conditions":"Coronavirus Disease 2019, COVID-19","enrollment":787},{"nctId":"NCT03201185","phase":"PHASE4","title":"Renin-angiotensin System Blockade Benefits in Clinical Evolution and Ventricular Remodeling After Transcatheter Aortic Valve Implantation (RASTAVI)","status":"UNKNOWN","sponsor":"Hospital Clínico Universitario de Valladolid","startDate":"2018-02-10","conditions":"Transcatheter Aortic Valve Replacemen, Angiotensin-Converting Enzyme Inhibitors","enrollment":194},{"nctId":"NCT04335786","phase":"PHASE4","title":"Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease","status":"TERMINATED","sponsor":"Radboud University Medical Center","startDate":"2020-04-17","conditions":"Acute Respiratory Distress Syndrome, SARS-CoV-2, COVID","enrollment":23},{"nctId":"NCT05007054","phase":"","title":"Long-Term Outcomes in Patients With Three-Vessel Disease","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Dalian Medical University","startDate":"2021-05-01","conditions":"Three Vessel Coronary Disease","enrollment":4300},{"nctId":"NCT04769778","phase":"PHASE4","title":"Renin Angiotensin System Blockade in Renal Transplant Patients With Presence of PECs in Urine","status":"UNKNOWN","sponsor":"Josep M Cruzado","startDate":"2020-02-19","conditions":"Chronic Kidney Allograft Nephropathy","enrollment":180},{"nctId":"NCT04351724","phase":"PHASE2, PHASE3","title":"Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2020-04-16","conditions":"COVID-19","enrollment":500},{"nctId":"NCT03335904","phase":"PHASE4","title":"AT1R Blockade and Periodic Breathing During Sleep in Hypoxia","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2018-01-01","conditions":"Sleep Disordered Breathing, Hypoxia, Respiration; Sleep Disorder","enrollment":14},{"nctId":"NCT02200822","phase":"PHASE4","title":"Systematic Withdrawal of Neurohumoral Blocker Therapy in Optimally Responding CRT Patients","status":"COMPLETED","sponsor":"Hasselt University","startDate":"2014-07","conditions":"Heart Failure (HF)","enrollment":80},{"nctId":"NCT02832973","phase":"PHASE4","title":"Sequential Nephron Blockade vs. Dual Blockade Renin-angiotensin System + Bisoprolol in Resistant Arterial Hypertension","status":"COMPLETED","sponsor":"Sao Jose do Rio Preto Medical School","startDate":"2015-09","conditions":"Hypertension Resistant to Conventional Therapy","enrollment":72},{"nctId":"NCT02744456","phase":"EARLY_PHASE1","title":"N-of-1 Trials for Blood Pressure Medications in Adults","status":"COMPLETED","sponsor":"Columbia University","startDate":"2014-08-01","conditions":"Hypertension, High Blood Pressure","enrollment":10},{"nctId":"NCT00913393","phase":"PHASE2","title":"Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy","status":"TERMINATED","sponsor":"Kyntra Bio","startDate":"2009-02","conditions":"Type 2 Diabetes Mellitus, Diabetic Nephropathy, Diabetic Kidney Disease","enrollment":46},{"nctId":"NCT00745953","phase":"PHASE4","title":"Regression of Fatty Heart by Valsartan Therapy","status":"WITHDRAWN","sponsor":"University of Texas Southwestern Medical Center","startDate":"2007-08","conditions":"Metabolic Syndrome, Lipotoxicity","enrollment":""},{"nctId":"NCT01132768","phase":"PHASE4","title":"The Confirmatory Olmesartan Plaque Regression Study","status":"TERMINATED","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2010-05","conditions":"Essential Hypertension, Carotid Plaque","enrollment":114},{"nctId":"NCT01292694","phase":"PHASE1","title":"Contribution of Angiotensin II to Supine Hypertension in Autonomic Failure","status":"TERMINATED","sponsor":"Vanderbilt University","startDate":"2011-03","conditions":"Hypertension, Pure Autonomic Failure, Multiple System Atrophy","enrollment":12},{"nctId":"NCT03526042","phase":"NA","title":"Angiotensin-II Receptor Antibodies Blockade With Losartan in Patients With Lupus Nephritis","status":"UNKNOWN","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2017-09-10","conditions":"Atherosclerosis, Lupus Nephritis","enrollment":40},{"nctId":"NCT00125645","phase":"PHASE4","title":"Left Ventricular Function After Acute Myocardial Infarction (AMI). Treatment With Angiotensin 2-Receptor Blockade (GLOBAL-Study)","status":"COMPLETED","sponsor":"University of Southern Denmark","startDate":"2005-03-01","conditions":"Myocardial Infarction","enrollment":200},{"nctId":"NCT03432468","phase":"NA","title":"Effect of Fully Blocking Type 1 Angiotensin Receptor on Target Organ Damage of Postmenopausal Hypertensive Women","status":"UNKNOWN","sponsor":"LanZhou University","startDate":"2018-04-01","conditions":"Hypertension","enrollment":102},{"nctId":"NCT01684748","phase":"PHASE4","title":"Angiotensin II Blockade and Inflammation in Obesity","status":"COMPLETED","sponsor":"Virginia Polytechnic Institute and State University","startDate":"2009-02","conditions":"Overweight, Obese, Prehypertension","enrollment":20},{"nctId":"NCT00067990","phase":"PHASE4","title":"Angiotensin II Blockade for Chronic Allograft Nephropathy","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2002-12","conditions":"Kidney Disease, Proteinuria","enrollment":153},{"nctId":"NCT01715584","phase":"PHASE4","title":"Is There an Adverse Drug Reaction Between Renin-Angiotensin System Blockade and Inhaled Anesthetics","status":"UNKNOWN","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2012-07","conditions":"Hypertension","enrollment":80},{"nctId":"NCT03219632","phase":"","title":"Fimasartan on Hypertensive Cardiac Disease With Left Ventricular Hypertrophy Estimated by ECG","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2012-06-05","conditions":"Left Ventricular Hypertrophy, Hypertension","enrollment":72},{"nctId":"NCT01734096","phase":"PHASE4","title":"Renal Response to Lower Body Negative Pressure in Pre-hypertensive States","status":"COMPLETED","sponsor":"PD Dr. Grégoire Wuerzner","startDate":"2009-05","conditions":"Hypertension, Obesity, White Coat Hypertension","enrollment":78},{"nctId":"NCT00498368","phase":"PHASE4","title":"Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2009-02","conditions":"IgA Nephropathy","enrollment":34},{"nctId":"NCT01377285","phase":"PHASE4","title":"Renoprotection by Pentoxifylline and Angiotensin Receptor Blocker in Chronic Kidney Disease (CKD)","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2010-06","conditions":"Chronic Renal Failure","enrollment":350},{"nctId":"NCT01454583","phase":"","title":"Registry for Ambulant Therapy With RAS-Inhibitors in Hypertension-patients in Germany","status":"COMPLETED","sponsor":"Stiftung Institut fuer Herzinfarktforschung","startDate":"2008-10","conditions":"Arterial Hypertension","enrollment":15337},{"nctId":"NCT01827202","phase":"PHASE4","title":"RAS Quantification in Patients With Aliskiren or Candesartan","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2012-12","conditions":"Hypertension, Chronic Kidney Disease, Proteinuria","enrollment":24},{"nctId":"NCT00878969","phase":"PHASE3","title":"Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3","status":"TERMINATED","sponsor":"Vanderbilt University","startDate":"2010-01","conditions":"Oxidative Stress, Endothelial Dysfunction","enrollment":78},{"nctId":"NCT00208767","phase":"PHASE2","title":"Effect of Valsartan on Carotid Artery Disease","status":"COMPLETED","sponsor":"Emory University","startDate":"2005-02","conditions":"Carotid Artery Diseases, Atherosclerosis","enrollment":120},{"nctId":"NCT00922311","phase":"PHASE4","title":"Aliskiren for Proteinuric IgAN Despite Angiotensin Blockade","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2009-07","conditions":"IgA Nephropathy","enrollment":25},{"nctId":"NCT01525888","phase":"NA","title":"Renin-angiotensin-aldosterone System (RAAS) Blockade and Contrast Induced Nephropathy","status":"COMPLETED","sponsor":"Soroka University Medical Center","startDate":"2012-02","conditions":"Radiographic Contrast Agent Nephropathy","enrollment":100},{"nctId":"NCT01432106","phase":"PHASE1","title":"The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome","status":"WITHDRAWN","sponsor":"University of Michigan","startDate":"2011-02","conditions":"Hypertension, Metabolic Syndrome","enrollment":""},{"nctId":"NCT00961207","phase":"PHASE4","title":"Triple Blockade of the Renin Angiotensin Aldosterone System in Diabetic (Type 1&2) Proteinuric Patients","status":"TERMINATED","sponsor":"Cook County Health","startDate":"2009-08","conditions":"Microalbuminuria, Macroalbuminuric Diabetic Nephropathy, Diabetes","enrollment":2},{"nctId":"NCT01011062","phase":"NA","title":"Effect of Angiotensin Receptor Blockade on Insulin Resistance and Adipose Tissue Cytokines in Type 2 Diabetes","status":"COMPLETED","sponsor":"Institute for Clinical and Experimental Medicine","startDate":"2004-01","conditions":"Insulin Resistance, Type 2 Diabetes","enrollment":23},{"nctId":"NCT01713270","phase":"NA","title":"Renal Sympathetic Denervation in Patients With Drug-resistant Hypertension and Symptomatic Atrial Fibrillation","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2012-07","conditions":"Hypertension, Atrial Fibrillation","enrollment":200},{"nctId":"NCT00732069","phase":"PHASE2","title":"Study of Inflammation and Oxidative Stress in Persons Undergoing Dialysis","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2008-08","conditions":"End Stage Renal Failure on Dialysis, Complication of Hemodialysis","enrollment":19},{"nctId":"NCT01116180","phase":"NA","title":"Cognitive Function and Electrocardiogram (ECG) During Hypoglycemia and Blockade of the Renin-angiotensin System","status":"COMPLETED","sponsor":"Louise Faerch","startDate":"2010-04","conditions":"Type 1 Diabetes, Hypoglycemia","enrollment":9},{"nctId":"NCT01737138","phase":"NA","title":"Renal Sympathetic Denervation in Patients With Chronic Kidney Disease and Resistant Hypertension","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2012-11","conditions":"Chronic Kidney Disease","enrollment":100},{"nctId":"NCT00865449","phase":"PHASE3","title":"Spironolactone and Prevention of Peritoneal Fibrosis in Peritoneal Dialysis","status":"COMPLETED","sponsor":"Instituto Nacional de Cardiologia Ignacio Chavez","startDate":"2008-07","conditions":"End Stage Renal Disease","enrollment":20},{"nctId":"NCT00930995","phase":"PHASE2","title":"Angiotensin Receptor Blockade as an Anti-Fibrotic Intervention in Patients With Chronic Hepatitis C","status":"WITHDRAWN","sponsor":"Kaiser Permanente","startDate":"","conditions":"Hepatitis C","enrollment":""},{"nctId":"NCT01036659","phase":"PHASE2","title":"Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema","status":"UNKNOWN","sponsor":"Bernstein, Jonathan A., M.D.","startDate":"2010-05","conditions":"Angioedema","enrollment":50},{"nctId":"NCT01541267","phase":"PHASE4","title":"The Effect of Various Types of the Renin-angiotensin-aldosterone System Blockade on Proteinuria","status":"COMPLETED","sponsor":"Medical University of Gdansk","startDate":"2009-12","conditions":"Chronic Kidney Disease, Proteinuria","enrollment":20},{"nctId":"NCT00275639","phase":"PHASE4","title":"The Effects of Angiotensin II Receptor Blockade on Kidney Function and Scarring After Liver Transplant","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2004-12","conditions":"Liver Transplant Recipients","enrollment":62},{"nctId":"NCT00587470","phase":"PHASE4","title":"Angiotensin-II Blockade in Mitral Regurgitation","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"1998-08","conditions":"Mitral Regurgitation","enrollment":60},{"nctId":"NCT00155246","phase":"PHASE4","title":"Efficacy of Pentoxifylline on Chronic Kidney Disease","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2004-07","conditions":"Chronic Kidney Disease","enrollment":60},{"nctId":"NCT00221845","phase":"PHASE3","title":"Effect of Strict Blood Pressure Control and ACE-Inhibition on Progression of Chronic Renal Failure in Pediatric Patients","status":"COMPLETED","sponsor":"Heidelberg University","startDate":"1998-01","conditions":"Children, Chronic Renal Failure, Hypertension","enrollment":400},{"nctId":"NCT00990639","phase":"PHASE1, PHASE2","title":"Effect of Candesartan in Alcoholic Liver Fibrosis","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2005-09","conditions":"Alcoholic Liver Disease","enrollment":85},{"nctId":"NCT00294775","phase":"PHASE3","title":"Effect of Angiotensin II Receptor Blockers (ARB) on Left Ventricular Reverse Remodelling After Aortic Valve Replacement in Severe Valvular Aortic Stenosis","status":"UNKNOWN","sponsor":"Odense University Hospital","startDate":"2006-02","conditions":"Aortic Valve Stenosis, Left Ventricular Hypertrophy, Atrial Fibrillation","enrollment":140},{"nctId":"NCT00893425","phase":"PHASE4","title":"Effect of Renin Angiotensin System Blockade on the Fas Antigen (CD95) and Asymmetric Dimethylarginine (ADMA) Levels in Type-2 Diabetic Patients With Proteinuria","status":"COMPLETED","sponsor":"Gulhane School of Medicine","startDate":"2008-01","conditions":"Proteinuria, Diabetic Nephropathy, Chronic Kidney Disease","enrollment":78},{"nctId":"NCT00863252","phase":"PHASE4","title":"Mycophenolate Mofetil for IgA Nephropathy","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2002-03","conditions":"IGA Nephropathy","enrollment":40},{"nctId":"NCT00235287","phase":"PHASE4","title":"Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease","status":"UNKNOWN","sponsor":"Herlev Hospital","startDate":"2005-09","conditions":"Kidney Failure, Chronic, Cardiovascular Diseases","enrollment":60},{"nctId":"NCT00674596","phase":"PHASE4","title":"The Effect of Renin Angiotensin System Blockage (RAS) Blockade On PTX3 Levels In Diabetic Patients With Proteinuria","status":"COMPLETED","sponsor":"Gulhane School of Medicine","startDate":"2006-01","conditions":"Diabetes, Proteinuria, Renin Angiotensin System","enrollment":60},{"nctId":"NCT00001534","phase":"","title":"Long Term Effects of Enalapril and Losartan on Genetic Heart Disease","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1996-09","conditions":"Hypertrophic Cardiomyopathy, Left Ventricular Hypertrophy, Myocardial Ischemia","enrollment":112},{"nctId":"NCT00572312","phase":"NA","title":"Optimalization of Nephroprotection Using Atorvastatin (Sortis)","status":"COMPLETED","sponsor":"Medical University of Gdansk","startDate":"2005-02","conditions":"Chronic Kidney Disease, Proteinuria","enrollment":""},{"nctId":"NCT00528385","phase":"NA","title":"Optimalization of Nephroprotection Using Agents Inhibiting Renin-Angiotensin-Aldosterone System","status":"COMPLETED","sponsor":"Medical University of Gdansk","startDate":"2005-03","conditions":"Chronic Kidney Disease, Proteinuria","enrollment":""},{"nctId":"NCT00212901","phase":"NA","title":"High Dose Ace Inhibitor Therapy Versus Combination of ACE and ARB Therapy","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2004-08","conditions":"Diabetic Kidney Disease","enrollment":30},{"nctId":"NCT00395005","phase":"","title":"Correlation of Urinary Kallikrein With Cytokines, Proteinuria and Renal Function in Chronic Renal Disease Patients","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2006-10","conditions":"Chronic Kidney Disease","enrollment":50},{"nctId":"NCT00367562","phase":"PHASE4","title":"Inhibition of the Renin Angiotensin System Plus Corticosteroids for the Treatment of Proteinuria in IGA Nephropathy","status":"COMPLETED","sponsor":"Hospital Britanico","startDate":"1996-01","conditions":"IGA Nephropathy","enrollment":20},{"nctId":"NCT00240019","phase":"NA","title":"Maximizing the Benefit of Renin-Angiotensin Blocking Drugs in Diabetic Renal Disease.","status":"COMPLETED","sponsor":"Stanford University","startDate":"2003-12","conditions":"Diabetic Nephropathy","enrollment":30},{"nctId":"NCT00361023","phase":"NA","title":"Effects of Losartan on Insulin Sensitivity and Secretion in Type 2 Diabetes and Nephropathy","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2006-01","conditions":"Type 2 Diabetes, Diabetic Nephropathy","enrollment":25},{"nctId":"NCT00320879","phase":"PHASE4","title":"Optimal Dose of Irbesartan for Renoprotection in Type 2 Diabetic Patients With Persistent Microalbuminuria","status":"COMPLETED","sponsor":"Steno Diabetes Center Copenhagen","startDate":"2003-09","conditions":"Type 2 Diabetes, Microalbuminuria","enrollment":52}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":372,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"angiotensin blockade","genericName":"angiotensin blockade","companyName":"The University of Hong Kong","companyId":"the-university-of-hong-kong","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Angiotensin blockade inhibits the renin-angiotensin-aldosterone system (RAAS) to reduce vasoconstriction and lower blood pressure. Used for Hypertension, Heart failure, Post-myocardial infarction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}